Anti-Epileptic Drugs Market Growth Insights | 2027 Industry Value Touches US$ 11,904.8 Million In Terms Of Revenue By 2027

SEATTLE, March 31, 2021, (PHARMIWEB) — Global Anti-epileptic Drugs Market, by Generation (First Generation, Second Generation, and Third Generation), By Route of Administration (Oral and Intravenous), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$  7,155.6 million in 2019 and is estimated to exhibit a CAGR of 6.6%over the forecast period (2019-2027), as highlighted in a new report published by Coherent Market Insights.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1701

The number of available anti-epilepsy drugs has doubled over the past several decades as the benefits of anti-epilepsy medicines are higher than the possible side-effects from the medicine. Moreover, the U.S. FDA has approved 28 drugs for the treatment of epilepsy and many generic versions of anti-epileptic drugs have been launched by manufacturers.

The U.S. FDA has only approved anticonvulsant medications for seizure disorders in children. Moreover, the currently available newer anti-seizure drugs have simple pharmacokinetics and more limited effects on liver metabolism, thus driving growth of the anti-epileptic drugs market for pediatrics.

The increasing improvements in efficacy of medications of treating epilepsy is expected to fuel growth of the anti-epileptic drugs market over the forecast period. For instance, newer drugs have exhibited better efficacy, owing to better pharmacokinetic profiles and fewer drug interactions than the classic first-generation drugs. For instance, the third-generation drugs developed by UCB’s Keppra (levetiracetam) and GlaxoSmithKline’s (GSK’s) Lamictal (lamotrigine) transitioned rapidly to the ‘Blockbuster’ status and have replaced the older gold standards in most of the markets as first-line treatments. According to the Epilepsy Foundation report of 2013, the newer third-generation AEDs have provided complete control over seizures to over half of the patients with epilepsy and reduced the number of seizures in another 20-30% of patients, thereby proving the success rate of the newer AEDs.

Browse 35 Market Data Tables and 30 Figures spread through 201 Pages and in-depth TOC on “Global Anti-epileptic Drugs Market, by Generation (First Generation, Second Generation, and Third Generation), by Route of Administration (Oral and Intravenous), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2027”

To know the latest trends and insights related to global anti-epileptic drug market press release, click the link below: https://www.coherentmarketinsights.com/press-release/anti-epileptic-drugs-market-2982

Key Takeaways of the Global Anti-epileptic Drugs Market:

• The global anti-epileptic drug market expected to exhibit a CAGR of 6.6% over the forecast period (2019-2027), owing to emergence of novel efficacious anti-epileptic drugs
• Among generation, third generation segment is expected to account for major revenue share by 2027, owing to rising demand for third generation anti-epileptic drugs, which is rapidly outpacing the first generation and second generation anti-epileptic drugs, mostly for the treatment of children and adolescents.
• Major players operating in the global anti-epileptic drug market include Novartis  AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., Mylan N.V., Bausch Health Companies Inc., and UCB S.A.

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://bit.ly/2PHL90z

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837